Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,223.03
(
-1.06%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 66051

Sunday, 06/26/2011 12:09:49 PM

Sunday, June 26, 2011 12:09:49 PM

Post# of 257580
SNY’s headline in this PR from ADA is misleading:

http://finance.yahoo.com/news/Sanofi-Announces-Positive-prnews-2993290208.html?x=0&.v=1

Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen

In fact, this open-label study missed its main objective, which was to show that Lantus + Apidra was superior to Novolog 70/30. From the same PR:

The study results supported the non-inferiority of Lantus® plus up to 1 injection of Apidra® versus two–injections of premixed insulin, while in the Lantus® plus up to 3 injections of Apidra® arm, superiority versus premixed insulin was not shown.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today